APP23 mice as a model of Alzheimer's disease: An example of a transgenic approach to modeling a CNS disorder

CNS Spectrums

Volumn 10, Issue 3, 2005, Pages 207-222

  Van Dam, Debby ^a   Vloeberghs, Ellen ^a   Abramowski, Dorothee ^b   Staufenbiel, Matthias ^b   De Deyn, Peter Paul ^a,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; DEGENERATIVE DISEASE; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

EID: 16844382906     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900010051     Document Type: Review

References (123)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741-766.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.
3. Schellenberg GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA. 1995;92:8552-8559.
4. Cruts M, Van Broeckhoven C. Molecular genetics of Alzheimer's disease. Ann Med. 1998;30:560-565.
5. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664-670.
6. Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997;277:822-824.
7. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55:964-968.
8. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol. 1991;20:736-748.
9. van Zutphen LFM, De Deyn PP. Animal use in experimental neuropathology: provisions for animal welfare and ethics. Neurosci Res Commun. 2000;26:49-160.
10. De Deyn PP, D'Hooge R, van Zutphen LFM. Animal models of human disorders - general aspects. Neurosci Res Commun. 2000;26:141-148.
11. Braak H, Braak E, Strothjohann M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett. 1994;171:1-4.
12. Nelson PT, Greenberg SG, Saper CB. Neurofibrillary tangles in the cerebral cortex of sheep. Neurosci Lett. 1994;170:187-190.
13. Cole GM, Frautschy SA. Animal models of Alzheimer's disease. Alz Dis Rev. 1997;2:33-41.
14. Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav. 2001;73:873-886.
15. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122-126.
16. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983;219:1184-1190.
17. Spangler EL, Rigby P, Ingram DK. Scopolamine impairs learning performance of rats in a 14-unit T-maze. Pharmacol Biochem Behav. 1986;25:673-679.
18. Pepeu G, Casamenti F, Pedata F, Cosi C, Pepeu IM. Are the neurochemical and behavioral changes induced by lesions of the nucleus basalis in the rat a model of Alzheimer's disease? Proc Neuropsychopharmacol Biol Psychiatry. 1986;10:541-551.
19. Santucci AC, Haroutunian V, Davis KL. Pharmacological alleviation of combined cholinergic/noradrencrgic lesion-induced memory deficits in rats. Clin Neuropharmacol. 1991;14(suppl 1):S1-S8.
20. Muir JL, Page KJ, Sirinathsinghji DJ, Robbins TW, Everitt BJ. Excitotoxic lesion of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav Brain Res. 1993;57:123-131.
21. Decker MW, Majchrzak MJ, Anderson DJ. Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 1992;572:281-285.
22. Miwa C, Ueki A. Effects of entorhinal cortex lesions on learning behavior and on hippocampus in the rat. Psychiatry Clin Neurosci. 1996;50:223-230.
23. Eijkenboom M, Van Der Staay FJ. Spatial learning deficits in rats after injection of vincristine into the dorsal hippocampus. Neuroscience. 1999;91:1299-1313.
24. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373:523-527.
25. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
26. Janus C, Pearson J, McLaurin J, et al. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-982.
27. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287-13292.
28. Sturchler-Pierrat C, Staufenbiel M. Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model Ann N Y Acad Sci. 2000;920:134-139.
29. Kuo YM, Kokjohn TA, Beach TG, et al. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem. 2001;276:12991-12998.
30. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311-324.
31. Calhoun ME, Burgermeister P, Phinney AL, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 1999;96:14088-14093.
32. Winkler DT, Bondolfi L, Herzig MC, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619-1627.
33. Winkler DT, Biedermann L, Tolnay M, et al. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol. 2002;51:790-793.
34. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673-1684.
35. Bornemann KD, Wiederhold KH, Pauli C, et al. Aβ-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001;158:63-73.
36. Stalder M, Deller T, Staufenbiel M, et al. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 2001;22:427-434.
37. Burbach GJ, Hellweg R, Haas CA, et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci. 2004;24:2421-2430.
38. Burbach GJ, Dehn D, Del Turco D, Staufenbiel M, Deller T. Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition. Glia. 2004;48:76-84.
39. Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets. 2004;8:391-399.
40. Gartner U, Bruckner MK, Krug S, Schmetsdorf S, Staufenbiel M, Arendt T. Amyloid deposition in APP23 mice is associated with the expression of cyclins in astrocytes but not in neurons. Acta Neuropathol (Berl). 2003;106:535-44.
41. Phinney AL, Deller T, Stalder M, et al. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci. 1999;19:8552-8559.
42. West MJ, Coleman PD, Flood DG, et al. Differences in the pattern of hippocampal neuron loss in normal aging and Alzheimer's disease. Lancet. 1994;344:769-772.
43. Regeur L, Jensen GB, Pakkenberg H, et al. No global neurocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol Aging. 1994;15:347-352.
44. Calhoun ME, Wiederhold KH, Abramowski D, et al. Neuron loss in APP transgenic mice. Nature. 1998;395:755-756.
45. Bondolfi L, Calhoun M, Ermini F, et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515-522.
46. Mueggler T, Sturchler-Pierrat C, Baumann D, et al. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci. 2002;22:7218-7224.
47. Mueggler T, Baumann D, Rausch M, et al. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J Neurosci. 2003;23:8231-8236.
48. Mueggler T, Meyer-Luehmann M, Rausch M, et al. Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis. Eur J Neurosci. 2004;20:811-817.
49. Beckmann N, Schuler A, Mueggler T, et al. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci. 2003;23:8453-8459.
50. Krucker T, Schuler A, Meyer EP, et al. Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer's disease. Neurol Res. 2004;26:507-516.
51. Okamura N, Suemoto T, Shiomitsu T, et al. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J Mol Neurosci. 2004;24:247-255.
52. Okamura N, Suemoto T, Shimadzu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004;:24:2535-2541.
53. Suemoto T, Okamura N, Shiomitsu T, et al. in vivo labeling of amyloid with BF-108. Neurosci Res. 2004;48:65-74.
54. Boncristiano S, Calhoun ME, Kelly PH, et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci. 2002;22:3234-3243.
55. Van Dam D, Marescau B, Engelborghs S, et al. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int. 2005 Jan 17 [Epub ahead of print].
56. Diez M, Danner S, Frey P, et al. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis. 2003;14:579-594.
57. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev. 2001;36:60-90.
58. Lalonde R, Dumont M, Staufenbiel M, et al. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 2002;956:36-44.
59. Van Dam D, D'Hooge R, Staufenbiel M, et al. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17:388-396.
60. Kelly PH, Bondolfi L, Hunziker D, et al. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging. 2003;24:365-378.
61. Dumont M, Strazielle C, Staufenbiel M, et al. Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation. Brain Res. 2004;1024:113-121.
62. Parvathy S, Davies P, Haroutunian V, et al. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-contaming amyloid plaques and cognitive decline. Arch Neurol. 2001;58:2025-2032.
63. Moran PM, Higgins LS, Cordell B, et al. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci USA. 1995;92:5341-5345.
64. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562-21570.
65. Gordon MN, King DL, Diamond DM, et al. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001;22:377-385.
66. Hsiao KK, Borchelt DR, Olson K, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203-1218.
67. D'Hooge R, Nagels G, Westland CE, et al. Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein. Neuroreport. 1996;7:2807-2811.
68. Kumar-Singh S, Dewachter I, Moechars D, et al. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol Dis. 2000;7:9-22.
69. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860-866.
70. Kuo YM, Beach TG, Sue LI et al. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for Aβ deposition in Alzheimer disease. Mol Med. 2001;7:609-618.
71. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav. 1997;31:197-211.
72. Tulving E. Multiple memory systems and consciousness. Hum Neurobiol. 1987;6:67-80.
73. Shinosaki K, Nishikawa T, Takeda M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin Neurosci. 2000;54:611-620.
74. Page KJ, Everitt BJ, Robbins TW, et al. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience. 1991;43:457-472.
75. Riekkinen P Jr, Kuitunen J, Riekkinen M. Effects of scopolamine infusions into the anterior and posterior cingulate on passive avoidance and water maze navigation. Brain Res. 1995;685:46-54.
76. Deacon RM, Bannerman DM, Kirby BP, et al. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res. 2002;133:57-68.
77. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatments. J Clin Psychiatry. 1987;48(suppl):9-15.
78. De Deyn PP, Rabhem K, Rasmussen A, et al. A randomized trial of risperidone, placebo; and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
79. De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacological agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001;62(suppl 21):19-22.
80. Witting W, Kwa IH, Eikelenboom P, et al. Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease. Biol Psychiatry. 1990;27:563-572.
81. Vloeberghs E, Van Dam D, Engelborghs S, et al. Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur Neurosci. 2004;20:2757-2766.
82. Meyer-Luehmann M, Stalder M, Herzig MC, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370-377.
83. Refolo LM, Pappolla MA, Malester B, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
84. Jick H, Zornberg GL, Jick SS, et al. Stalins and the risk of dementia. Lancet. 2000;365:1627-1631.
85. Lütjohann D, Papassotiropoulos A, Björkhem I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000;41:195-198.
86. Papassotiropoulos A, Lütjohann D, Bagli M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27-32.
87. Lütjohann D, Brzezinka A, Barth E, et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002;43:1078-1085.
88. Förstermann U, Gath I, Schwarz P, et al. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol. 1995;50:1321-1332.
89. Luth HJ, Holzer M, Gartner U, et al. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimers disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 2001;913:57-67.
90. Beal ME Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 2000;23:298-304.
91. Buchner M, Huber R, Sturchler-Pierrat C, et al. Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice. Neuroscience. 2002;114:285-289.
92. Feig S, Lipton P. N-methyl-D-aspartate receptor activation and Ca2+ account for poor pyramidal cell structure in hippocampal slices. J Neurochem. 1990;55:473-483.
93. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31-39.
94. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271-276.
95. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228-3233.
96. Larson J, Lynch G, Games D, et al. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999;840:23-35.
97. Moechars D, Dewachter I, Lorent K, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483-6492.
98. Fitzjohn SM, Morton RA, Kuenzi F, et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. Neurosci. 2001;21:4691-4698.
99. Roder S, Danober L, Pozza MF, et al. Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. Neuroscience. 2003;120:705-720.
100. Van Dam D, Abramowski D, Staufenbiel M et al. Symptomatic effects of Donepezil, Rivastigmine, Gaiantamme and Memantine on cognitive deficits in the APP23 model. Psychopharmacology. 2005 Jan 15 [Epub ahead of print].
101. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science. 2002;298:1379.
102. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The LXR ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. Biol Chem. 2005;280:4079-4088.
103. Bayer TA, Schafer S, Simons A, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA. 2003;100:14187-H192.
104. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824-828.
105. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101(suppl 2):14657-14662.
106. Marlow L, Cain M, Pappolla MA, et al. Beta-seen-case processing of the Alzheimer's amyloid protein precursor (APP). J Mol Neurosci. 2003;20:233-239.
107. Koldamova RP, Lefterov IM, Ikonomovic MD, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter Al expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem. 2003;278:13244-13256.
108. Brown J 3rd, Theisler C, Silberman S, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004;279:34674-34681.
109. Sun Y, Yao J, Kim TW, et ai. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 2003;278:27688-27694.
110. Hesse L, Beher D, Masters CL, et al. The beta A4 amyloid precursor protein binding to copper. FEBS Lett. 1994;349:109-116.
111. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with aizheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem. 2000;25:1219-1233.
112. Borchardt T, Schmidt C, Camarkis J, et al. Differential effects of zinc on amyloid precursor protein (APP) processing in copper-resistant variants of cultured Chinese hamster ovary cells. Cell Mol Biol. 2000;46:785-795.
113. Maynard CJ, Cappai R, Volitakis I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 2002;277:44670-44676.
114. Phinney AL, Drisaldi B, Schmidt SD, et al. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci USA. 2003;100:14193-14198.
115. Leber P. Observations and suggestions on antidemencia drug development. Alzheimer Dis Assoc Disord. 1996;10(suppl 1):31-35.
116. Bodick N, Forette F, Hadler D, et al. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord. 1997;11(suppl 3):50-53.
117. Kittner B, De Deyn PP, Erkinjuntti T. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Ann N Y Acad Sci. 2000;903:535-541.
118. Dewachter I, van Dorpe J, Spittaels K, et al. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol. 2000;35:831-841.
119. Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology in transgenic mice overexpressing V717Fβ-amyloid precursor protein. J Neuropathol Exp Neurol. 2001;60:357-368.
120. Götz J. Tau and transgenic animal models. Brain Res Brain Res Rev. 2001;35(3):266-286.
121. Götz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Aβ 42 fibrils. Science. 2001;293:1491-1495.
122. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402-405.
123. Crawley JN, Belknap JK, Collins A, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl). 1997;132:107-124.